166 related articles for article (PubMed ID: 34590148)
1. Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists.
Hoffmann JHO; Knoop C; Enk A; Hadaschik EN
Acta Derm Venereol; 2021 Sep; 101(10):adv00568. PubMed ID: 34590148
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.
Hoffmann JHO; Knoop C; Schäkel K; Enk AH; Hadaschik EN
Acta Derm Venereol; 2021 May; 101(5):adv00462. PubMed ID: 33903917
[TBL] [Abstract][Full Text] [Related]
3. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
5. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.
Schwarz CW; Loft N; Rasmussen MK; Nissen CV; Dam TN; Ajgeiy KK; Egeberg A; Skov L
Acta Derm Venereol; 2021 Oct; 101(10):adv00579. PubMed ID: 34642768
[TBL] [Abstract][Full Text] [Related]
7. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
[TBL] [Abstract][Full Text] [Related]
8. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.
Atalay S; van der Schoot LS; Vandermaesen L; van Vugt LJ; Eilander M; van den Reek JMPA; de Jong EMGJ
Acta Derm Venereol; 2021 May; 101(5):adv00463. PubMed ID: 33903920
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
[TBL] [Abstract][Full Text] [Related]
11. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
12. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Van Muijen ME; Thomas SE; Groenewoud HMM; Otero ME; Ossenkoppele PM; Njoo MD; Dodemont SRP; Kop EN; Berends MAM; Koetsier MIA; Mommers JM; Körver JEM; Tupker RA; De Bruin-Weller MS; Weppner-Parren LJMT; Peters B; Kleinpenning MM; Kuijpers ALA; Arnold WP; Van Lümig PPM; Van den Reek JMPA; De Jong EMGJ
Acta Derm Venereol; 2022 May; 102():adv00712. PubMed ID: 35356990
[TBL] [Abstract][Full Text] [Related]
13. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
14. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
15. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
Hoffmann JHO; Knoop C; Schäkel K; Enk AH; Hadaschik EN
J Dermatol; 2021 Jun; 48(6):835-843. PubMed ID: 33470023
[TBL] [Abstract][Full Text] [Related]
17. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
18. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
[TBL] [Abstract][Full Text] [Related]
19. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.
Andersen CSB; Kvist-Hansen A; Siewertsen M; Enevold C; Hansen PR; Kaur-Knudsen D; Zachariae C; Nielsen CH; Loft N; Skov L
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047086
[TBL] [Abstract][Full Text] [Related]
20. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
